Core Viewpoint - Lensar has terminated its planned acquisition by Alcon due to unresolved regulatory concerns, primarily from the US Federal Trade Commission (FTC) [1][3]. Group 1: Acquisition Details - Alcon had agreed to acquire Lensar for an implied value of approximately $356 million in March 2025 [1][2]. - The acquisition was intended to enhance Alcon's femtosecond laser-assisted cataract surgery (FLACS) portfolio with Lensar's technologies, including the Ally robotic cataract laser treatment system [2][5]. - The deal was pending for nearly one year, with initial expectations for a mid-to-late 2025 closing [2]. Group 2: Regulatory Concerns - The FTC indicated its intention to oppose the transaction, leading both companies to conclude that terminating the merger was in their best interests [1][3]. - The deadline for completing the acquisition was set for April 23, 2026, with a possible extension to July 23, 2026 [3]. Group 3: Company Statements and Future Outlook - Lensar's president and CEO expressed disappointment over the outcome but reaffirmed the company's commitment to advancing cataract surgery through the growth of the ALLY robotic cataract laser system [4]. - Since its commercial introduction in 2022, the ALLY system has been recognized as a significant advancement in refractive cataract surgery, contributing to market share gains and procedure growth for Lensar [5].